Based on the experience accumulated in our institution, we would offer induction chemotherapy with TPF for three cycles for all physically fit patients with non-metastatic T4 SMARCB1-deficient sinonasal carcinoma, followed by immediate imaging assessment with an MRI and CT scan of the head and neck region (Supplementary Figure S6). The gene discussed is SMARCB1; the disease is nasal cavity and paranasal sinus carcinoma.